Novo Nordisk Partners with Amazon to Boost Drug Discovery
Novo Nordisk and Amazon Web Services (AWS) have partnered to accelerate drug discovery with AI. A co-innovation hub in London will facilitate efforts to reduce the time to market for future medicines.
Novo Nordisk and Amazon Web Services (AWS) recently announced a strategic partnership to accelerate drug discovery and modernise Novo Nordisk’s operations through agentic AI and cloud technologies. As part of the partnership, Novo Nordisk and AWS have created a co-innovation hub in London where engineers and scientists from both companies are using AWS AI technologies alongside Novo Nordisk data and insights to compress the path from drug target to first human dose.
“Partnering with AWS is about making AI a driver of innovation across Novo Nordisk,” said Mike Doustdar, president and CEO of Novo Nordisk. “By combining our scientific expertise with AWS’ tools and purpose-built services for the life sciences industry, while also creating a dedicated co-innovation hub within our existing facility in London, we are accelerating discovery and developing responsible AI solutions that will create real progress for people living with serious chronic diseases.”
Novo Nordisk has selected AWS as its preferred cloud provider and strategic AI partner. The partnership brings together Novo Nordisk's deep therapeutic knowledge across chronic diseases and AWS's world-leading cloud and AI services, secure and scalable infrastructure, and life sciences technologies.
Novo Nordisk has already seen measurable results from this collaboration, including reducing clinical documentation time and empowering more than 25,000 employees to boost productivity. The agreement builds on a longstanding relationship and will create the secure foundations needed to turn ideas into new therapies for patients around the world. This includes using services such as Amazon Bio Discovery and Amazon Bedrock to identify drug targets, design new therapies faster, and connect genomic, imaging, and clinical data so that breakthroughs in early research can shape clinical trial design. Novo Nordisk will also leverage Amazon Bedrock AgentCore to drive efficiencies across its operations through AI agents.
"Every part of our work with Novo Nordisk comes back to one thing: getting the right medicine to patients, faster," said Matt Garman, CEO, AWS. "Novo Nordisk has chosen AWS as their strategic AI partner to fundamentally change how medicines are discovered and developed using services such as Amazon Bio Discovery and Amazon Bedrock. We’re excited to partner with Novo Nordisk so that these technologies, AWS Forward Deployed Engineers, and Novo Nordisk’s industry-leading science teams can help compress drug discovery timelines, securely process complex datasets, and scale findings across therapeutic areas.”
